Neoeriocitrin

Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease^[1][2][3][4]. In Vitro:Neoeriocitrin (2-20 μg/mL; 72 h) modulates MC3T3-E1 cell proliferation in a dose-dependent manner^[1].
Neoeriocitrin (2-20 μg/mL; 5 days) increases MC3T3-E1 cell ALP activity in a dose-dependent manner^[1].
Neoeriocitrin (2 μg/mL; 4-8 days) upregulates expression of osteogenic marker genes Runx2, COL I, and OCN in MC3T3-E1 cells^[1].
Neoeriocitrin (2 μg/mL; 5 days) partially rescues PD98059 (HY-12028)-induced inhibition of ALP activity in MC3T3-E1 cells^[1].
Neoeriocitrin (2 μg/mL; 4-8 days) partially rescues PD98059-induced downregulation of COL I and OCN mRNA expression in MC3T3-E1 cells^[1].
Neoeriocitrin (2.5-200 μM; 1-14 days) significantly and sustainably promotes the proliferation of human dental pulp stem cells^[2].
Neoeriocitrin (2.5-10 μM; 7-21 days) enhances the osteogenic differentiation of human dental pulp stem cells, as measured by increased osteogenic gene and protein expression, alkaline phosphatase activity, and mineralization^[2].
Neoeriocitrin (100 μM; 1 h) directly binds to Beclin1 in human dental pulp stem cells, as identified by increased thermal stability of Beclin1 in thermal proteome profiling^[2].
Neoeriocitrin (2.5-10 μM; 48 h) induces autophagy in human dental pulp stem cells, as measured by reduced P62 levels, increased LC3-II/I ratio, enhanced autophagosome formation, and increased autophagosome number detected via transmission electron microscopy^[2].
Neoeriocitrin (5 μM) requires Beclin1 as a critical mediator for its induced autophagy and osteogenic differentiation in human dental pulp stem cells, as Beclin1 knockdown attenuates and Beclin1 overexpression amplifies Neoeriocitrin's effects^[2].
Neoeriocitrin (5 μM; 3-12 h) stabilizes Beclin1 protein in human dental pulp stem cells by inhibiting ubiquitin-mediated proteasomal degradation, thereby extending Beclin1 half-life^[2].
Neoeriocitrin (6×10⁴ μM; 2 h pre-incubation, 22 h co-incubation with Aβ25-35) protects Aβ25-35 (HY-P0128)-damaged PC12 cells by reducing apoptosis, upregulating ERβ expression, inhibiting P38 protein phosphorylation, and improving cholinergic system function^[4]. In Vivo:Neoeriocitrin (P3 hDPSCs cultured with Neoeriocitrin for 5 days and then combined with Bio-Oss bone grafting material at a seeding density of 1 × 10⁷ cells) significantly enhances new bone formation in rat critical-sized calvarial defects, with increased autophagy marker expression (Beclin1, LC3) and reduced P62 in regenerating bone tissue^[2].